Business Context and Reporting Period
This Form 8-K was filed by Lion Biotechnologies, Inc. on June 8, 2015. The filing reports a change in senior management, specifically the appointment of a new Chief Financial Officer (CFO) and the resignation of the prior CFO. Note: The request metadata references "IOVANCE BIOTHERAPEUTICS, INC.", but the filing text explicitly identifies the registrant as Lion Biotechnologies, Inc.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and employment terms.
Material Changes
- Appointment of New CFO: Molly Henderson was appointed Chief Financial Officer effective June 8, 2015.
- Resignation of Prior CFO: Michael Handelman resigned as CFO effective June 8, 2015, with continued employment through June 30, 2015.
- Compensation for New CFO:
- Annual salary: $275,000.
- Stock options: 200,000 shares at an exercise price of $10.69 (closing price on June 8, 2015).
- Vesting schedule: 66,672 shares vest on June 8, 2016; remaining shares vest quarterly over the subsequent two years (16,666 shares per quarter).
- Separation Arrangements for Prior CFO:
- Acceleration of vesting: 25,000 unvested restricted shares and options for 18,750 shares vest on June 30, 2015.
- Severance: One month's salary.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of business risks. It is a standard disclosure of executive personnel changes and associated compensatory arrangements.
Investor Verification Checklist
- Verify the correct registrant name (Lion Biotechnologies, Inc.) versus the metadata reference (IOVANCE BIOTHERAPEUTICS, INC.).
- Confirm the vesting schedule and exercise price ($10.69) for the 200,000 stock options granted to Molly Henderson.
- Review the specific terms of the accelerated vesting for Michael Handelman's restricted stock and options.
- Check subsequent filings to confirm the transition of duties and any further changes to the executive team.